Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 28, 2023
TickeronGET DAILY SIGNALS

Swing Trader Downtrend Protection v.2 - Generating 7.47% for ZOM

Capitalizing on the Swing: How Downtrend Protection v.2 (TA) Delivered strong performance for ZOM Amidst Pharmaceuticals' Varied Market Cap

In a dynamic space, the pharmaceutical industry is teeming with companies of varied sizes, capabilities, and financial magnitudes. The average market capitalization across the Pharmaceuticals sector stands at a formidable $2.3 billion, reflecting the robust financial backing of most entities in this area. However, the spread within the group is notably vast, ranging from a modest $246 million to a whopping $77.8 billion.

The pharmaceutical giant Zoetis Inc. (ZTS) stands at the pinnacle of this range, boasting the highest market capitalization at $77.8 billion. The smallest market cap within this group belongs to PEMTF, with a comparatively meager valuation of $246 million.

However, amidst this variegated financial landscape, Zomedica Corp. (ZOM) has carved out a niche for itself. The company recently experienced a notable surge in its returns, thanks to the strategic implementation of the Downtrend Protection v.2 (TA) trading technique, better known as the Swing trading method.

For the uninitiated, Swing trading involves taking advantage of the natural oscillation of stock prices, capitalizing on the upswing, and protecting capital during downturns. This approach offers opportunities for higher returns and risk management, especially in volatile markets.

Zomedica, by adopting the Downtrend Protection v.2 (TA), managed to generate a commendable strong performance, a testament to the efficacy of this trading approach. This strategy, designed to shield investments during periods of market volatility, appears to have worked in favor of ZOM.

The use of this technical analysis tool showcases ZOM's ability to strategize its moves amidst a volatile and diverse market environment, thereby optimizing returns for its investors. It is worth noting that the swing trading strategy employed is not about getting the highest possible peak, but about gaining consistent returns. This underlines ZOM's prudent investment approach.

In conclusion, Zomedica's case demonstrates that market capitalization, while important, is not the sole determinant of success in the pharmaceutical industry. Strategic trading mechanisms like Downtrend Protection v.2 (TA) can help companies optimize their returns, even in the face of volatile market conditions and varied capitalizations.

Related Ticker: ZOMDF

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interesting Articles
A.I. Advisor
published General Information

General Information

a company that develops medication for animals

Industry MedicalNursingServices

Industry
Pharmaceuticals Major
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.